Remember January 2014? “Monster,” by Eminem and Rihanna was No. 1 in the U.S., while “Lone Survivor” topped the box office and, for a few days at least, Intercept Pharmaceuticals (ICPT) was a $450 stock.
It’s not anymore, as the chart below illustrates, and it fell about 25 percent further on Thursday after the FDA put out a note that the company’s lead drug, Ocaliva, increased the risk of liver injury and death in some patients. Intercept is down another 14 percent today.
About the Author Reprints
